Search research articles
Contact Us
Filters
Showing results (831-840 of 1,834) with videos related to
Page
of 184
Sort By:
Mabs
|
July 8, 2025
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies
Frank R Brennan, J Ryan Polli, Jean Sathish, et al.
Mabs
|
June 25, 2025
Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by <i>k</i>D, rheology, and Raman spectroscopy
Olivia Noelle Eskens, Sabitoj Singh Virk, Akashdeep Singh Virk, et al.
Mabs
|
June 25, 2025
Developing drug-like single-domain antibodies (VHH) from in vitro libraries
M Frank Erasmus, Andre A R Teixeira, Esteban Molina, et al.
Mabs
|
September 12, 2025
Rational design of antibodies with pH-dependent antigen-binding properties using structural insights from broadly neutralizing antibodies against α-neurotoxins
Jack Wade, Nina Štrancar, Monica L Fernández-Quintero, et al.
Mabs
|
February 15, 2024
Structure- and machine learning-guided engineering demonstrate that a non-canonical disulfide in an anti-PD-1 rabbit antibody does not impede antibody developability
Wei-Ching Liang, Hongkang Xi, Dawei Sun, et al.
Mabs
|
February 13, 2024
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma
Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, et al.
Mabs
|
March 13, 2024
Do antibody CDR loops change conformation upon binding?
Chu'nan Liu, Lilian M Denzler, Oliver E C Hood, et al.
Mabs
|
March 18, 2024
Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
W van der Wulp, W Luu, M E Ressing, et al.
Mabs
|
July 1, 2024
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
Brian Kelley
Mabs
|
July 23, 2024
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy
Patrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, et al.
Page
of 184
Search research articles
Search
Showing results (831-840 of 1,834) with videos related to
Sort By:
Page
of 184
Mabs
|
July 8, 2025
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies
Frank R Brennan, J Ryan Polli, Jean Sathish, et al.
Mabs
|
June 25, 2025
Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by <i>k</i>D, rheology, and Raman spectroscopy
Olivia Noelle Eskens, Sabitoj Singh Virk, Akashdeep Singh Virk, et al.
Mabs
|
June 25, 2025
Developing drug-like single-domain antibodies (VHH) from in vitro libraries
M Frank Erasmus, Andre A R Teixeira, Esteban Molina, et al.
Mabs
|
September 12, 2025
Rational design of antibodies with pH-dependent antigen-binding properties using structural insights from broadly neutralizing antibodies against α-neurotoxins
Jack Wade, Nina Štrancar, Monica L Fernández-Quintero, et al.
Mabs
|
February 15, 2024
Structure- and machine learning-guided engineering demonstrate that a non-canonical disulfide in an anti-PD-1 rabbit antibody does not impede antibody developability
Wei-Ching Liang, Hongkang Xi, Dawei Sun, et al.
Mabs
|
February 13, 2024
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma
Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, et al.
Mabs
|
March 13, 2024
Do antibody CDR loops change conformation upon binding?
Chu'nan Liu, Lilian M Denzler, Oliver E C Hood, et al.
Mabs
|
March 18, 2024
Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
W van der Wulp, W Luu, M E Ressing, et al.
Mabs
|
July 1, 2024
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras
Brian Kelley
Mabs
|
July 23, 2024
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy
Patrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, et al.
Page
of 184